Incyte/INCY
13:30
14:25
15:15
16:10
17:00
1D1W1MYTD1YMAX
About Incyte
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Ticker
INCY
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
Wilmington, United States
Employees
2,524
Website
www.incyte.com
Incyte Metrics
BasicAdvanced
$13B
Market cap
17.89
P/E ratio
$3.30
EPS
0.74
Beta
-
Dividend rate
Price and volume
Market cap
$13B
Beta
0.74
Financial strength
Current ratio
3.472
Quick ratio
3.291
Long term debt to equity
0.536
Total debt to equity
0.693
Interest coverage (TTM)
283.78%
Management effectiveness
Return on assets (TTM)
6.89%
Return on equity (TTM)
15.13%
Valuation
Price to earnings (TTM)
17.89
Price to revenue (TTM)
3.51
Price to book
2.46
Price to tangible book (TTM)
2.59
Price to free cash flow (TTM)
16.72
Growth
Revenue change (TTM)
8.58%
Earnings per share change (TTM)
127.92%
3-year revenue growth
11.71%
3-year earnings per share growth
14.79%
What the Analysts think about Incyte
Analyst Ratings
Majority rating from 25 analysts.
Incyte Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$881M
-13.08%
Net income
$170M
-15.67%
Profit margin
19.24%
-2.98%
Incyte Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
$0.99
$1.10
$1.06
$0.64
-
Expected
$0.83
$1.02
$1.16
$0.84
$1.09
Surprise
19.81%
7.44%
-8.38%
-24.03%
-
Incyte News
AllArticlesVideos
Incyte: The Worst Has Been Avoided
Seeking Alpha·2 weeks ago
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Wire·4 weeks ago
Malignant Mesothelioma Pipeline Landscape Analysis, 2024 - Incyte's INCB001158 and Polaris' Pegargiminase Lead the Way in Mechanism-Specific Interventions
GlobeNewsWire·4 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Incyte stock?
Incyte (INCY) has a market cap of $13B as of July 03, 2024.
What is the P/E ratio for Incyte stock?
The price to earnings (P/E) ratio for Incyte (INCY) stock is 17.89 as of July 03, 2024.
Does Incyte stock pay dividends?
No, Incyte (INCY) stock does not pay dividends to its shareholders as of July 03, 2024.
When is the next Incyte dividend payment date?
Incyte (INCY) stock does not pay dividends to its shareholders.
What is the beta indicator for Incyte?
Incyte (INCY) has a beta rating of 0.74. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.
Buy or sell Incyte stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.